Onkologie. 2010:4(3):164-166
Late effects of treatment Hodgkin’s Lymphoma
- Oddělení klinické hematologie FNKV Praha
Progress in the treatment of Hodgkin’s lymphoma (HL) is one of the huge successes in modern oncology. According to the stage and
presence of risk factors, up to 85–90 % of patients achieve long-term remission with life expectancy of 40 years. New problem to deal
with at the moment are the late adverse effects caused by preceeding therapy of HL: cardiotoxicity, secondary neoplasia, lung toxicity,
impairement of fertility (azoospermia, amenorhea), impairement of the thyroid function, imunosupression with infectious complications,
psychosocial problems. Other complications can occur: impairement of soft tissue (muscles, gastrointestinal organs), bones and
neurological disorders. Current knowledge of late-onset toxicity due to the treatment of HL is based on the observation of patients who
were treated by therapeutical methods which are not being used any more.
Keywords: Hodgkin lymphoma, chemotherapy, radiotherapy, late effects
Published: July 1, 2010 Show citation
References
- Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21(18): 3431-3439.
Go to original source... 
Go to PubMed... - Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988; 318. Go to original source... Go to PubMed...
- Aleman BM, van Leeuwen FE. Are We Improving the LongTerm Burden of Hodgkin's Lymphoma Patients with Modern Treatment? Hematol Oncol Clin N Am 21 (2007) 961-975. Go to original source... Go to PubMed...
- Hoppe RT, Mauch PM, Armitage JO, Diehl V, Weiss LM: Hodgkin Lymphoma, 2nd Edition, Lippincott Williams & Wilkins, 2007, in Chapter 23, Late Effects.
- Adam Z, Vorlíček J, Koptíková J, et al. Obecná onkologie a podpůrná léčba, Grada, 2003, p. 685-697 (in Psychologické a psychiatrické problémy onkologických nemocných a ošetřujícího personálu), p. 711-713. (In zhoubné nádory a reprodukce).
- Marková J, Mociková H, Feltl D, Kozak T. Thyroid Diseases after Therapy for Hodgkin´s Lymphoma. Blood 2003, Vol. 102, 11, abs. 4866. ASH 45th Annual Meeting, Dec. 6-9, 2003, San Diego.
- Marková J, Zídka M, Feltl D, Móciková H, Kozák T. Osteonecrosis as a complication of treating Hodgkin´s lymphoma after BEACOPP chemotherapy. Annals of Oncology, Vol. 16 (suppl 5), 2005, abs. 269, 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, 8.-11. June, 2005.
- Markova J, Klaskova K, Vydra J, Polivka J, Zikavska L, Cap F, Vlachova A, Vernerova Z, Sturma J, Kozak T. Severe Bleomycin Induced Pneumonitis in Patients with Hodgkin's Lymphoma. Haematologica 2007; 92(suppl. 5), P071. 7th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 4.-7. November, 2007.
- Klaskova K, Kral Z, Flechtner H, Prasko J, Dragomirecka E, Smardova L, Hynkova L, Voglova M, Kalvodova L, Vorlicek J, Kozak T, Markova J. Quality of Life in Long - Term Survivors of Hodgkin s Lymphoma Treated Within German Hodgkin Lymphoma Study Group Trials in the Czech Republic: A Retrospective Study of Patients from 1995 to 2003. Haematologica 2007; 92(suppl. 5).
- Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21(19): 3601-3608. Go to original source... Go to PubMed...
- Diehl V, Brillant C, Engert A, et al. HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG). J Clin Oncol 2005; 23(16S): 6506. Go to original source...